Key Takeaways
- • BIOTECanada welcomed measures in Budget 2026 aimed at strengthening Canada's life sciences sector, according to a Business Wire release.
- • The budget expands Scientific Research and Experimental Development (SR&ED) eligibility to include certain regulatory approval and intellectual property costs.
- • The budget includes new investment incentives and additional funding for strategic sectors, including biomanufacturing.
- • BIOTECanada CEO Wendy Zatylny called the SR&ED change "an important step for biotechnology companies."
Summary
BIOTECanada, the national biotechnology industry association, has welcomed measures in Canada's federal Budget 2026 that it says can help strengthen the country's life sciences sector, according to a press release distributed via Business Wire from Ottawa. The organization highlighted three areas: expanded support for research and development, new investment incentives, and additional funding for strategic sectors, including biomanufacturing.
The most specific change cited is the expansion of Scientific Research and Experimental Development (SR&ED) eligibility to cover certain regulatory approval and intellectual property costs. Wendy Zatylny, President and CEO of BIOTECanada, said the change "is an important step for biotechnology companies." For biotech firms, whose development spending often includes lengthy regulatory and patent-related outlays, broader SR&ED eligibility could affect the after-tax cost of R&D programs.
The release frames the budget as building on existing momentum in the sector. The primary source does not provide specific dollar amounts for the new funding or incentive programs, and additional details on the scale or timing of the measures were not available in the reporting reviewed.
The most specific change cited is the expansion of Scientific Research and Experimental Development (SR&ED) eligibility to cover certain regulatory approval and intellectual property costs. Wendy Zatylny, President and CEO of BIOTECanada, said the change "is an important step for biotechnology companies." For biotech firms, whose development spending often includes lengthy regulatory and patent-related outlays, broader SR&ED eligibility could affect the after-tax cost of R&D programs.
The release frames the budget as building on existing momentum in the sector. The primary source does not provide specific dollar amounts for the new funding or incentive programs, and additional details on the scale or timing of the measures were not available in the reporting reviewed.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.